MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts - Wikidata - awgldk - TriplyDB

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts

http://www.wikidata.org/entity/Q37425601

about

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions Mito-priming as a method to engineer Bcl-2 addiction.A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199 Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Rapid Optimization of Mcl-1 Inhibitors using Stapled Peptide Libraries Including Non-Natural Side Chains.Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance.Examination of a second node of translational control in the unfolded protein response.Mitochondria: gatekeepers of response to chemotherapy Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Evading apoptosis in cancer.Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection.Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C.BH3 profiling in whole cells by fluorimeter or FACS Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML BCL2 suppresses PARP1 function and nonapoptotic cell death.Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines.Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells.Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.

P2860

Q26828031-8E5D9CD2-5241-4263-87A5-8E7488CCB68C Q27334195-3F980173-9BEF-409E-B366-B8A41E53EE70 Q30466831-A44428B9-0F63-4AE7-9957-9584AA3564AB Q33806087-43CBD061-A804-4BC0-B203-C1C8EE117218 Q34059078-8E6B9278-0C85-4C27-8E14-BFB4C74FB727 Q34135298-F9337139-1CCE-478F-B0DC-595A1BFD7624 Q34135542-99CB21E2-AC52-47EB-92D6-575F706EC6A0 Q34173253-BB5430D5-4C17-4DBE-9601-25511FDCD2AC Q34369809-C7EAE5A7-2725-4710-99BC-F43FDC7B9C94 Q34392488-9C384B06-2A15-42D4-8FE3-ADF89A0A3CD1 Q35170975-7D4A4189-65B5-451C-8A80-18371A2BD2D9 Q35172545-3F17078E-EBA4-4F2C-86AB-4440F916A8A9 Q35251905-866A90A2-2D3B-4C80-9637-1095953A63C0 Q35266213-63AA3124-97BD-4AB9-8CCA-BE0C50F7CF39 Q35761070-6B559BD6-357D-4D1D-B941-F0B4CDADD7BD Q35917117-7719901F-08FD-44A9-8FB0-B78D26A6D519 Q35943976-3543143A-BDEE-4E36-A31F-FC11B73C7761 Q37168900-3D5F011A-C4AD-4C32-A769-45320588CAEA Q37347485-010B1666-D442-414B-9B79-134697838261 Q37552035-6EF068DA-5EC6-42C8-8FC4-B2BA138969A7 Q37725409-99B34C86-D28D-4C41-951A-B7681364D164 Q37854419-E8DC9E32-9CBE-47F2-8AB7-C84CC6472349 Q37865381-874D70DB-F33D-488E-883A-93E1984AE7A5 Q38130013-0F303799-FE8B-4B00-AF70-74D39BB36968 Q38307680-D6DE2672-76A9-49D9-98C7-F711C17A2B4E Q38398064-1A622900-80D8-404F-ADED-1ACD06E60E99 Q38457498-11900C9D-978B-44D4-A541-3FC96869B094 Q38630410-04D557E2-CBEB-4987-86FD-E770DD422449 Q38954134-FCF57644-5D98-4E82-A825-8218CB43C8F2 Q38957684-2229C36D-EA59-431C-952C-7771F9526060 Q39038744-2A0B44AD-57F1-4174-82CD-4325D4BD7CB2 Q39162409-EEC0F7E2-33D4-4EEA-8B19-6272D4C9581F Q39260268-40A0F483-76B5-423A-BB7A-7968DBA6C0A2 Q39332703-DAB48D7E-7828-4372-9B0A-9FA76167EC7B Q42534915-0BA9C7C6-CA8B-4F72-9386-23244C6CC596 Q42906307-64A1C3A1-F35D-4A82-AB48-1BC9A7B6886F Q47252515-9392AAD7-A412-4759-A6E9-4D180BEDBB8A Q48316021-934BC752-D734-4046-9A94-782AC13C339A

P2860

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts

http://www.wikidata.org/entity/Q37425601

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

MCL-1-dependent leukemia cells ...... n BCL-2-dependent counterparts

@en

MCL-1-dependent leukemia cells ...... BCL-2-dependent counterparts.

@nl

type

label

MCL-1-dependent leukemia cells ...... n BCL-2-dependent counterparts

@en

MCL-1-dependent leukemia cells ...... BCL-2-dependent counterparts.

@nl

prefLabel

MCL-1-dependent leukemia cells ...... n BCL-2-dependent counterparts

@en

MCL-1-dependent leukemia cells ...... BCL-2-dependent counterparts.

@nl

P1433

Q37425601-E42BC2C8-B018-4CCA-99E8-09B43B5F2701

P1476

Q37425601-790429E3-747F-44CA-AB9B-97EAA7899A68

P2093

Q37425601-1428ADC2-8621-4B67-BFCF-FE208080847F

Q37425601-1A89C565-0D93-4E7F-BB7E-3BD6DAA26D67

Q37425601-37C6CDAC-E896-4B55-8A39-852EAD8FC5B9

Q37425601-5DB3D8F6-0E86-441F-AC2B-B64E8CB56921

Q37425601-9480810E-5DBA-4ED9-971C-331CE6C7E94A

P2860

Q37425601-0F6D8C50-F8F8-49BE-A972-408F564BE81E

Q37425601-114B0DA5-3506-4ADD-92A6-53939EC8EBBA

Q37425601-13D9CD0A-13EC-4FFB-B670-9AEF6A11950F

Q37425601-18B5CFFB-C014-46DD-8BB5-61662F8A409C

Q37425601-285DA673-F9A2-4FA6-99B0-B1145EB18BCF

Q37425601-2C2068D1-71BE-44C5-979E-D8084ED72979

Q37425601-3862471C-B80A-4B63-BAC4-6C791EEDFE95

Q37425601-3A304D6F-2D51-41CF-A2F7-93BE82B27F27

Q37425601-3C3DD765-50CB-4410-8574-8B4ABA598081

Q37425601-3D71A6AD-5AD9-4786-8CF9-3462A4AA427A

P304

Q37425601-47C87965-F838-4D44-866F-76BBF409361F

P31

Q37425601-AD45A5D1-CDC3-4463-9C11-40539381FBA2

P356

Q37425601-830E9E8F-A4A8-4DC6-9731-ACBFD880F3FE

P407

Q37425601-9480A1E5-4367-4F5E-ADFC-5A02DDEA29D8

P433

Q37425601-8C12DF5C-63F5-4C9F-9094-2174CDF1AEA3

P478

Q37425601-3FE55891-C7DC-4EA3-944B-59BFC0B8E06D

P577

Q37425601-57CADBC5-7F0B-4037-8843-14F4CB345CE1

P5875

Q37425601-F2F81D6C-3A02-4147-BD7A-5E2299B1803C

P698

Q37425601-835DCE8A-86BE-4B39-883B-AED513A29198

P921

Q37425601-8252FE9B-273D-4F5F-9EA7-552B4D49718A

Q37425601-E81E7A19-D2F7-42C5-B67E-A487A0D3FFA4

P932

Q37425601-61509137-23EE-42CC-B24D-C99A8E1FB4C2

P356

P1433

Journal of Cell Biology

P1476

MCL-1-dependent leukemia cells ...... n BCL-2-dependent counterparts

@en

P2093

Anthony Letai

http://www.w3.org/2001/XMLSchema#string

Derek Yecies

http://www.w3.org/2001/XMLSchema#string

Jeremy Ryan

http://www.w3.org/2001/XMLSchema#string

Joseph T Opferman

http://www.w3.org/2001/XMLSchema#string

Joslyn K Brunelle

http://www.w3.org/2001/XMLSchema#string

P2860

tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c

PUMA, a novel proapoptotic gene, is induced by p53

Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

Structural insights into the degradation of Mcl-1 induced by BH3 domains

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

P304

429-442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1083/JCB.200904049

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40041621

http://www.w3.org/2001/XMLSchema#string

P698

19948485

http://www.w3.org/2001/XMLSchema#string

P921

P932

2779245

http://www.w3.org/2001/XMLSchema#string